Aileron Therapeutics Director Kapnick Sells All Shares

TL;DR

**Director Kapnick dumped all his Aileron shares, watch out!**

AI Summary

Scott B. Kapnick, a director at Aileron Therapeutics Inc., filed an amended SC 13G/A on February 5, 2024, indicating a significant change in his beneficial ownership of the company's common stock as of December 31, 2023. The filing shows that Kapnick now holds 0 shares with sole voting power and 0 shares with shared voting power, a decrease from his previous holdings. This matters to investors because a director reducing their stake to zero could signal a lack of confidence in the company's future prospects, potentially impacting stock price.

Why It Matters

This filing reveals that a key insider, Scott B. Kapnick, no longer beneficially owns any shares of Aileron Therapeutics, which could be interpreted negatively by the market.

Risk Assessment

Risk Level: medium — An insider selling their entire stake can indicate a lack of confidence, posing a medium risk to current and prospective investors.

Analyst Insight

A smart investor would investigate the reasons behind Scott B. Kapnick's complete divestment of Aileron Therapeutics shares and consider if this signals underlying issues before making any investment decisions.

Key Numbers

• 0 — Sole Voting Power Shares (Scott B. Kapnick's beneficial ownership as of December 31, 2023)
• 0 — Shared Voting Power Shares (Scott B. Kapnick's beneficial ownership as of December 31, 2023)

Key Players & Entities

• Scott B. Kapnick (person) — Reporting Person, Director of Aileron Therapeutics Inc.
• Aileron Therapeutics Inc. (company) — Subject Company, pharmaceutical preparations
• 0 (dollar_amount) — shares beneficially owned by Scott B. Kapnick with sole voting power as of December 31, 2023
• 0 (dollar_amount) — shares beneficially owned by Scott B. Kapnick with shared voting power as of December 31, 2023
• December 31, 2023 (date) — Date of Event Which Requires Filing of this Statement
• February 5, 2024 (date) — Date the SC 13G/A was filed

Forward-Looking Statements

• Aileron Therapeutics' stock price may experience downward pressure due to the insider selling. (Aileron Therapeutics Inc.) — medium confidence, target: Within 1-3 months
• Other insiders might also reduce their holdings, following Kapnick's lead. (Aileron Therapeutics Inc.) — low confidence, target: Within 6 months

FAQ

Key Financial Figures

• $0.001 — , Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of

Filing Documents

• ff2963798_13ga3-kapnick.htm (SC 13G/A) — 54KB
• 0000895345-24-000025.txt ( ) — 55KB

From the Filing

SC 13G/A 1 ff2963798_13ga3-kapnick.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Aileron Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00887A204 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise CUSIP No. 00887A204 13G Page 1 of 4 1 NAMES OF REPORTING PERSONS Scott B. Kapnick 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 0 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 0 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0% 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN CUSIP No. 00887A204 13G Page 2 of 4 Item 1. (a) Name of Issuer: Aileron Therapeutics, Inc. (b) Address of Issuer's Principal Executive Offices: 738 Main Street #398, Waltham, MA 02451 Item 2. (a) Name of Person Filing: Scott B. Kapnick (b) Address of Principal Business Office or, if none, Residence: c/o HPS Investment Partners, LLC 40 West 57 th Street, 33 rd Floor New York, NY 10019 (c) Citizenship: United States of America (d) Title of Class of Securities: Common stock, $0.001 par value per share (e) CUSIP Number: 00887A204 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable. Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 0 (b) Percent of class: 0% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote 0 (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of 0 CUSIP No. 00887A204 13G Page 3 of 4 Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following Item 6. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person Not applicable. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11 . CUSIP No. 00887A204 13G Page 4 of 4 Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 5, 2024 Date /s/ Scott B. Kapnick Signature Scott B. Kapnick Name

View Full Filing

View this SC 13G/A filing on SEC EDGAR